BioSpace News Archive

Aviceda Therapeutics announced their upcoming oral and poster presentations at the 2023 Association for Research in Vision and Ophthalmology Annual meeting in New Orleans, LA., April 23-27, 2023.

Aisa Pharma, Inc. a private, clinical-stage biopharmaceutical company, announces that the National Institute of Neurological Disorders and Stroke (NINDS)- National Institutes of Health (NIH) have awarded the Preclinical Screening Pain Platform (PSPP) award to Aisa’s Profervia® (cilnidipine), a once-daily novel, investigational, oral calcium-channel antagonist.

INmune Bio, Inc. (NASDAQ: INMB) (the “Company”) today announced that the Company has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for the use of INKmune™ to treat metastatic castration-resistant prostate cancer (mCRPC).

Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company focused on early intervention orthopedics, today announced that it has received an additional 510(k) clearance from FDA for Tactoset Injectable Bone Substitute.

Nova Research Laboratories, LLC is pleased to announce the acquisition of Maryland-based CiPA Lab. Dr. Jason (Jiansong) Sheng, Ph.D., CEO of CiPA Lab, and his team will be a great benefit to expanding Nova’s preclinical capabilities.

Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”) announced today that it received notice from the U.S. Food and Drug Administration (FDA) that the FDA’s Office of Combination Products (OCP) completed its preliminary product classification and jurisdictional assessment of Celularity’s investigational FUSE Bone Void Filler (“FUSE”).

RELIEF THERAPEUTICS Holding SA announces the appointment of world-renowned gene therapy pioneer Guangping Gao, Ph.D. as the chair of the Company’s newly formed scientific advisory board.

Mabwell, an innovative biopharmaceutical company with the layout of whole industry chain, announced that the Denosumab solution for injection, which is developed by its wholly-owned subsidiary T-mab, has been formally approved for marketing by the National Medical Products Administration .

Harbour BioMed, a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immune-oncology and immunology, released annual results of full year 2022.

aVaxziPen, a biotech company developing a novel needle-free vaccine delivery platform, announces the presentation of data at the World Vaccine Congress in Washington, USA.